Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?

TheMotleyFool

0 0

Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?: https://g.foolcdn.com/editorial/images/785577/gettyimages-1665778558.jpg

One of the biggest narratives in the pharmaceutical space right now is that of weight-loss treatments.

Glucagon-like peptide 1 (GLP-1) agonists such as Ozempic and Wegovy are making significant headway among diabetes and obesity care patients. Both turned out to be blockbuster drugs, and are made by Danish pharmaceutical powerhouse Novo Nordisk (NYSE: NVO).

Investors have cheered Novo as the company continues dominating the fast-growing GLP-1 market. But with shares of Novo Nordisk surging 57% over the last 12 months, you may be wondering if the train has left the station.

Source Fool.com

Like: 0

NVO

Share